The binding assay, known as DRUGMATRIX, involves the use of a radioligand [125I] MCP-1 to bind with homologous single protein target Chemokine CCR2B. The assay is conducted in vitro using CHO-K1 cells and membrane subcellular fractions. Its type is described as a binding assay. Does this assay respond well to the molecule?